Improved photodynamic effect through encapsulation of two photosensitizers in lipid nanocapsules

Barras, Alexandre; Skandrani, Nadia; Pisfil, Mariano Gonzalez; Paryzhak, Solomiya; Dumych, Tetiana; Haustrate, Aurélien; Héliot, Laurent; Gharbi, Tijani; Boulahdour, Hatem; Lehen’kyi, V’yacheslav; Bilyy, Rostyslav; Szunerits, Sabine; Bidaux, Gabriel; Boukherroub, Rabah

doi:10.1039/c8tb01759j

Cited by 17 publications

(10 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, chlorin E6 was incorporated into nanoparticles via formation of ion complexes in order to increase absorption by the tumor (Lee et al, 2013). Encapsulation of drugs into delivery systems has been as area of extensive research over the last years (Rout et al, 2017;Barras et al, 2018;Fasiku et al, 2021;Karges et al, 2021;Mitchell et al, 2021). Although bioconjugation and encapsulation with targeting moieties seem to be critical approaches in order to develop more effective and specific PSs, it should also be borne in mind that an ideal PS should achieve high quantum yield, display long-wave absorption, cause low dark toxicity, demonstrate favorable pharmacokinetic properties, have high purity and stability (Wöhrle et al, 1998).…”

Section: History Of Photodynamic Therapymentioning

confidence: 99%

Photodynamic Therapy for the Treatment and Diagnosis of Cancer–A Review of the Current Clinical Status

2021

View full text Add to dashboard Cite

Photodynamic therapy (PDT) has been used as an anti-tumor treatment method for a long time and photosensitizers (PS) can be used in various types of tumors. Originally, light is an effective tool that has been used in the treatment of diseases for ages. The effects of combination of specific dyes with light illumination was demonstrated at the beginning of 20th century and novel PDT approaches have been developed ever since. Main strategies of current studies are to reduce off-target effects and improve pharmacokinetic properties. Given the high interest and vast literature about the topic, approval of PDT as the first drug/device combination by the FDA should come as no surprise. PDT consists of two stages of treatment, combining light energy with a PS in order to destruct tumor cells after activation by light. In general, PDT has fewer side effects and toxicity than chemotherapy and/or radiotherapy. In addition to the purpose of treatment, several types of PSs can be used for diagnostic purposes for tumors. Such approaches are called photodynamic diagnosis (PDD). In this Review, we provide a general overview of the clinical applications of PDT in cancer, including the diagnostic and therapeutic approaches. Assessment of PDT therapeutic efficacy in the clinic will be discussed, since identifying predictors to determine the response to treatment is crucial. In addition, examples of PDT in various types of tumors will be discussed. Furthermore, combination of PDT with other therapy modalities such as chemotherapy, radiotherapy, surgery and immunotherapy will be emphasized, since such approaches seem to be promising in terms of enhancing effectiveness against tumor. The combination of PDT with other treatments may yield better results than by single treatments. Moreover, the utilization of lower doses in a combination therapy setting may cause less side effects and better results than single therapy. A better understanding of the effectiveness of PDT in a combination setting in the clinic as well as the optimization of such complex multimodal treatments may expand the clinical applications of PDT.

show abstract

Section: History Of Photodynamic Therapymentioning

confidence: 99%

Photodynamic Therapy for the Treatment and Diagnosis of Cancer–A Review of the Current Clinical Status

2021

View full text Add to dashboard Cite

show abstract

“…Barras et al . (74) reported that the use of combination of two PS (Protoporphyrin IX, (PpIX) and Hypericin, (Hy)) encapsulated inside liposomes (LNCs) favored PDT. The spectroscopic studies showed that the encapsulation of both PS in the lipid core increases their solubilization and photophysical properties; besides, the encapsulation of both Ps into a liposome (PpIX–Hy‐loaded LNC25) incremented the phototoxicity in HeLa and MDA‐MB‐232 cells line and provided a synergistic effect.…”

Section: Use Of Drug Delivery Systems For Photosensitizersmentioning

confidence: 99%

Recent Photosensitizer Developments, Delivery Strategies and Combination‐based Approaches for Photodynamic Therapy^†

Mariño-Ocampo¹,

Dibona‐Villanueva

Álvarez

et al. 2022

Photochem & Photobiology

View full text Add to dashboard Cite

Photodynamic therapy of cancer (PDT) is a therapeutic technique, minimally invasive, which is currently used to treat cancerous lesions and tumors that have been in the spotlight for its potential over the recent decades. Nonetheless, PDT still needs further development to become a first-option treatment for patients. This review compiles recent progress in several aspects of the current research in the constantly growing area of PDT to overcome the main challenges as an attempt to serve as a guide and reference for newcomers into this research area. This review has been prepared to highlight the use of chemical modifications on photosensitizers to improve their solubility, photostability, selectivity and phototoxicity. Additionally, the use of liposomes and cavitands as drug delivery systems to aid in the biodistribution and bioaccumulation of photosensitizers is presented. Also, the combination of PDT with chemotherapy or immunotherapy as an option to boost and improve treatment outcomes is discussed. Finally, the inhibition of antioxidant enzymes as a strategy for a synergistic effect to ameliorate the performance of the photosensitizers in PDT is presented as an alternative for future researchers.

show abstract

“…The monomeric form of hypericin has been previously reported into lipid membrane structures 270 and nanoparticles. 265 The absorption spectrum of monomeric HYP has also been observed for hypericin in other systems such as biodegradable PLA NPs, 261 anti-HSA monoclonal antibodies, 253 solid lipid nanoparticles 259 or lipid nanocapsules. 258,265 In this latter example, a 3 nm hypsochromic shift regarding DMSO λmax, as in HYP@1, was described.…”

Section: Hypericin Encapsulationmentioning

confidence: 94%

“…265 The absorption spectrum of monomeric HYP has also been observed for hypericin in other systems such as biodegradable PLA NPs, 261 anti-HSA monoclonal antibodies, 253 solid lipid nanoparticles 259 or lipid nanocapsules. 258,265 In this latter example, a 3 nm hypsochromic shift regarding DMSO λmax, as in HYP@1, was described. 258 A value of 0.01-0.23% w/w was calculated as drug loading in HYP@1, which is quite similar to some examples of hypericin-loaded systems in Table 4.7.…”

Section: Hypericin Encapsulationmentioning

confidence: 94%

“…Additionally, it has been described that the absorption peak maxima of hypericin shifts to the red on increasing the solvent polarity. 230,240,265 Therefore, hypericin in the nanogels (λmax 596 nm) is in a more hydrophobic environment compared to both PBS (λmax 605 nm) and DMSO (λmax 599 nm), probably being located in hydrophobic pockets of the nanoparticles.…”

Section: Hypericin Encapsulationmentioning

confidence: 99%

See 1 more Smart Citation

Molecular nanogels as nanocarriers. Intracellular transport of photosensitizers and nitric oxide probes

Martínez¹

View full text Add to dashboard Cite

The need for nanocarriers in medicine arises from the increasing number of therapeutic and diagnostic agents whose efficacy is affected by nonspecific cell and tissue biodistribution, systemic and organ toxicity, poor solubility and bioavailability, or rapid metabolization and excretion. Nanogels show advantages over other nanoparticles: improved flexibility and biocompatibility, simple preparation, high water content, high stability and high loading capacity for both hydrophilic and hydrophobic molecules. However, the use of polymeric nanogels presents challenges associated with stimuli-triggered release, biodegradation, polydispersity and batch-to-batch reproducibility in the preparation of polymers. Molecular gels, formed by low molecular weight molecules, may represent an exciting alternative CHAPTER 6. CONCLUSIONS CHAPTER 7. EXPERIMENTAL SECTION ANNEXES ANNEXE I. Resumen en castellano ANNEXE II. Reprint of published papers CHAPTER 1 GENERAL INTRODUCTIONNANOPARTICLES AS CARRIERS 8 menopausal therapy) 51 and Taxol and Taxotere (with paclitaxel and docetaxel, for cancer treatment). 39 Liposomal Nanocarriers. Liposomes are spherical vesicles comprising one or more concentric lipid bilayers, with an aqueous polar core, a lipophilic bilayer compartment and a hydrophilic exterior. 54,55 Hydrophobic ingredients can be inserted into the lipid bilayer or sequestered in the core, whereas water-soluble molecules can be encapsulated in the core. The lipid bilayer is usually composed of phospholipids and sterols such as cholesterol, the latter controlling membrane permeability and fluidity. The physicochemical properties of liposomes are determined by the lipid composition, sterol concentration, surface charge and nanoparticle size. 56 For example, although liposomes enter the cell via endocytic processes, by adhering and fusing with the bilayer of the cell membrane, the overall surface charge tunes the cellular uptake: neutral liposomes do not readily interact with cells and release the content in the extracellular space, whereas positively charged liposomes readily interact with the negative charge on the cell surface via electrostatic forces. 57 Also, the conjugation of hydrophilic polymers, such as PEG, has been used to address the rapid elimination from the bloodstream due to opsonization and clearance by the liver and the spleen, which limits their bioavailability. 58 Ligand-targeted liposomes have also been engineered to promote sitespecific binding. 59 Liposomal nanocarriers can be engineered to respond to temperature and/or pH. 60,61 Due to their biodegradable and biocompatible properties, liposomes undoubtedly represent the most successful type of drug delivery systems to enhance therapeutic potency. Liposome nanocarriers reached the market in 1995 with Doxil, a liposome containing doxorubicin. Since then, ten further products have been approved by the FDA/European Medicines Agency (EMA) for clinical use, mostly for combination cancer therapy. 39 Exceptionally, AmBisome (carrying amphotericin B) is ...

show abstract

Improved photodynamic effect through encapsulation of two photosensitizers in lipid nanocapsules

Abstract: Encapsulation of two photosensitizers in lipid nanocapsules leads to enhanced photodynamic therapy efficiency.

Cited by 17 publications

References 49 publications

Photodynamic Therapy for the Treatment and Diagnosis of Cancer–A Review of the Current Clinical Status

Photodynamic Therapy for the Treatment and Diagnosis of Cancer–A Review of the Current Clinical Status

Recent Photosensitizer Developments, Delivery Strategies and Combination‐based Approaches for Photodynamic Therapy^†

Molecular nanogels as nanocarriers. Intracellular transport of photosensitizers and nitric oxide probes

Contact Info

Product

Resources

About

Improved photodynamic effect through encapsulation of two photosensitizers in lipid nanocapsules

Abstract: Encapsulation of two photosensitizers in lipid nanocapsules leads to enhanced photodynamic therapy efficiency.

Cited by 17 publications

References 49 publications

Photodynamic Therapy for the Treatment and Diagnosis of Cancer–A Review of the Current Clinical Status

Photodynamic Therapy for the Treatment and Diagnosis of Cancer–A Review of the Current Clinical Status

Recent Photosensitizer Developments, Delivery Strategies and Combination‐based Approaches for Photodynamic Therapy†

Molecular nanogels as nanocarriers. Intracellular transport of photosensitizers and nitric oxide probes

Contact Info

Product

Resources

About

Recent Photosensitizer Developments, Delivery Strategies and Combination‐based Approaches for Photodynamic Therapy^†